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Abstract: Recent evidence indicates that foamy viruses (FVs) are the oldest retroviruses 
(RVs) that we know and coevolved with their hosts for several hundred million years. This 
coevolution may have contributed to the non-pathogenicity of FVs, an important factor in 
development of foamy viral vectors in gene therapy. However, various questions on the 
molecular evolution of FVs remain still unanswered. The analysis of the spectrum of 
animal species infected by exogenous FVs or harboring endogenous FV elements in their 
genome is pivotal. Furthermore, animal studies might reveal important issues, such as the 
identification of the FV in vivo target cells, which than require a detailed characterization, 
to resolve the molecular basis of the accuracy with which FVs copy their genome. The 
issues of the extent of FV viremia and of the nature of the virion genome (RNA vs. DNA) 
also need to be experimentally addressed. 
Keywords: foamy viruses; retroviruses; hepadnaviruses; evolution; genetic conservation; 
recombination 
 
1. Introduction 
Retroviruses have gained a lot of general interest, because of the devastating human AIDS 
pandemic over the last 35 years, making HIV one of the best-studied viruses of all times. However, 
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lentiviruses, such as HIV, are not the most widespread of Retroviridae. The most prevalent of all 
retroviruses (RVs) are probably spumaretroviruses (or foamy viruses), a subfamily of RVs that has 
attracted altogether a group of approximately only 250 researchers from 10–15 labs worldwide over 
the same period of 35 years.  
This life in a scientific niche is also illustrated by the fact that while the PubMed database lists  
more than 330,000 items for the search criteria “HIV or AIDS”, the hits are only around 1,000 for  
“foamy virus”. The interest in foamy viruses (FVs) is increasing, since these viruses offer unique 
opportunities for RV research, due to their distinct replication strategy, distinguishing them from 
orthoretroviruses [1–3], in clinical applications as potential retroviral vectors [4–6], due to their  
non-pathogenicity in any species [3,4], and as a model virus for studying antiretroviral drugs for  
HIV-1, since FV integrase has been crystallized [7–9]. However, the particular molecular 
characteristics of a virus may be a reflection of its evolutionary success or failure. Additionally, in 
terms of evolutionary success and genome stability, no RV compares to FVs, as suggested by a 
number of recent studies. 
2. FV Sequence Conservation 
Viruses with an RNA genome or an RNA (pre-) genome phase in their replication cycle are  
likely to accumulate genetic changes over time [10,11]. Individuals infected chronically by such 
viruses generally present (if untreated for their infection) a dynamic swarm of genetically slightly 
different viral variants at any given moment [10–12]. In virology, this has been termed the 
quasispecies concept [10–12]. At the basis of this concept is the error-prone replication by the RNA 
polymerase or reverse transcriptase (RT) together with a high in vivo replication rate [10–12]. The 
errors due to these types of mutations can be in the range of 1:103 to 1:105 point mutations per 
replication cycle [10,11].  
This scenario may be further complicated by recombination events exchanging larger pieces of 
genetic information mainly between related viruses by replicase during genome copying [10,11]. 
Recombination events by template switching are well known for several virus families, such as 
picornaviruses, and have been investigated extensively (for a review, see [13]). Furthermore, in the 
case of viruses with segmented genomes, such as orthomyxoviruses, the exchange of whole segments 
may alter the features of the progeny substantially [10–13]. It is evident that genetic recombination  
or gene exchange (reassortment) in vivo requires the infection of one cell within one host by at least  
two viruses.  
Numerous examples of high genetic variability of the retroviral, hepadnaviral and positive (+) 
strand RNA virus families have been investigated in detail (HIV, hepatitis B virus (HBV) and hepatitis 
C virus (HCV) are only the most prominent ones causing chronic infections in humans [14–24]), while 
only a handful of examples for recombination were described for the non-segmented minus (−) strand 
RNA viruses [25]. 
However, FVs appear to be an exception to these general rules of RNA virus and retrovirus genetic 
variability, because their genome is highly stable [26–30]. The in vivo variation of FV genomes has 
been estimated to be around 1.7 × 10−8 substitutions per site per year, which was quite close to that of 
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mitochondrial DNA of 1.16 × 10−8; these values are unprecedented among viruses having an RNA 
phase in their replication cycle [28].  
Figure 1. The principal replication strategies of viruses making use of reverse transcription. 
While orthoretroviruses are RNA viruses, which replicate through a DNA intermediate and 
require integration for reproduction, hepadnaviruses are DNA viruses replicating through 
an RNA intermediate without the integration of their genome. FVs appear to functionally 
bridge these pathways, since they reverse transcribe (at least to a significant extent) late  
in replication (like hepadnaviruses) and must integrate their genome into the host cell 
genome (like orthoretroviruses). Furthermore, cellular exit of FV particles depends on their 
cognate glycoprotein as in hepadnaviruses, while budding of orthoretroviral particles is 
Env-independent (Figure adapted from [3]). RT, reverse transcriptase. 
 
Even hepadnaviruses, which are related to FVs in terms of their replication pathway (Figure 1), 
show a one thousand-fold higher in vivo point mutation rate upon chronic human infections [16], 
despite the fact that they have a much more compact genetic order with largely overlapping reading 
frames that puts constraints on the variability of hepadnaviruses [31]. Indeed, the common origin of 
retroviruses with hepadnaviruses has been suggested long ago [32,33], and FVs might represent this 
evolutionary link, from which both viral families evolved [34–36]. However, fossil viral records are 
not available to address this question. Thus, for the time being, the relation of FV genomes to 
orthoretroviruses and hepadnaviruses is more or less a functional one. Therefore, due to the accuracy 
of genome copying and sequence stability, an FV sequence can be used to determine the animal 
subspecies of its origin, provided the exclusion of trans-species infection [37]. This feature has 
practical consequences, for instance, by designing breeding strategies for non-human primates (NHPs). 
For obvious reasons, it is often impossible to obtain blood samples from wild or quasi-wild animals, 
particularly the great apes. However, methods have been adapted from experiences in AIDS-research 
to amplify FV sequences from fecal samples obtained without disturbing the animals [38]. Due to the 
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enormous genome conservation of FVs, such analyses revealed a phylogenetic co-distribution of the 
viruses with their hosts [37]. 
Investigations of whether the exceptionally high processivity, observed for the FV RT enzyme [39], 
reflected by the accuracy of in vitro genome copying and, thus, possibly an intrinsic feature of the FV 
RT, revealed a surprising observation: analysis of bacterially-expressed protein indicated that the 
fidelity of the FV RT enzyme approximated the one of HIV RT in a similar assay [40]. The overall 
mutation rates were 1.7 × 10−4 for prototype FV (PFV) and 7.5 × 10−5 for HIV, respectively [40]. Two 
thirds of PFV RT errors were due to deletions or small insertions [40]. Apparently, many more 
deletions or insertions were discovered for the FV enzyme than for the HIV RT. These in vitro 
findings resembled, in some way, deletions observed in the long terminal repeats (LTRs) upon FV 
amplification in cell culture [41,42]. 
The length of the LTRs is a striking feature of FV genomes (Figure 2). The U3 regions contribute  
to these by approximately 85%. In particular, the LTRs of FVs from primates have extraordinarily  
long U3 regions of more than 1,400 bps [41]. Approximately one third of the U3 regions of primate 
FVs are protein-encoding bet sequences (Figure 2). The possible functions of the sequence remainder, 
aside from relatively short DNA motifs required for the regulation of gene expression [43,44],  
are inadequately defined and need further characterization. Because the rest of the genome has  
protein-encoding and cis-acting RNA or DNA functions, or both [2,45,46], the deletions in the U3 
LTR region may be tolerated by virus replication in cell culture [41,42]. Such deletions were actually 
found upon obtaining proviral FV molecular clones from higher primates [47], and the detection of the 
undeleted LTRs [41,48] delayed their initial identification [49,50].  
Figure 2. Prototype foamy virus (PFV) genome organization with particular reference to 
the length and structure of the long terminal repeat (LTR) with the canonical U3, R and U5 
regions. The retroviral genes (gag, pro-pol, env) are abbreviated as usual. The FV 
accessory tas and orf-2 reading frames are shown, as well as the spliced reading frame, 
giving rise to the Bet protein. The start of transcription in the LTR is indicated by an arrow 
in the enlargement at the bottom. The numbers refer to lengths in kilobase pairs (kbp) or 
base pairs (bp). 
 
Another deletion that also occurs in vivo [41,48] is located in the coding region of the tas gene and 
contains the DNA copy of an almost full-length viral RNA, except approximately 200 bps, that 
includes the splice, which is normally needed to encode the Bet protein [51,52]. Since Tas is an 
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essential viral accessory protein that exerts its function in trans [49,53], the so-called ∆Tas genome 
behaves like a defective-interfering particle [2,3]. 
The low fidelity detected by the in vitro study of the FV RT prompted the analysis of viral 
replication in cell culture [54], similar to investigations correcting the initially-reported very low in 
vitro fidelity of HIV RT [55,56]. The determination of the FV RT error rate on a lacZ-gene fragment 
that also was used in vitro [40,54] revealed that the frequency of deletions now dropped to insignificant 
values, and that of miss-incorporations, due to point mutations, was now found to be around 4 × 10−4 
per site and replication cycle [54]. The vast majority of the point mutations were G –> A transitions, 
suggesting a role of APOBEC3 proteins in shaping the FV genome sequences (see below) [57].  
The FV accessory Bet protein has been identified to counteract cellular APOBEC3 proteins [58,59]. 
However, the prototype FV (PFV) isolate Bet is inefficient compared, for instance, to the Bet protein 
of feline FV (FFV) proviral plasmids in this respect ([60], M. Löchelt, personal communication). 
Probably this inefficiency, partially due to the adaptation of the PFV isolate to cell culture conditions, 
is responsible for some misleading findings on Bet function [61]. Furthermore, it remained unclear 
whether this inefficiency to counteract APOBEC3 or the rather low cellular bet gene expression levels 
obtained with the particular expression plasmid [54,62] or both reasons led only to an around 50% 
reduction of G –> A mutations identified in the target cells transduced by FV vectors [54]. In contrast, 
normally, the bet gene is highly expressed in naturally FV-infected cells [63–65]. 
It should be noted that even if one ignores all G –> A mutations, by assuming that Bet will prevent 
these in the in vivo situation, such an “idealized” FV RT error rate of around 1.1 × 10−5 point mutations 
per replication cycle would still remain [54]. This is significantly more than observed for FV in vivo 
replication and indicates that more constraints act on the virus that do not allow for in vivo genome 
variability. This difference may be due to the potential presence of a factor that negatively influences 
the accuracy of FV genome copying in the HEK 293T cells, used to produce the vector particles, or the 
cells lack a factor that positively regulates the FV RT fidelity, which is present in vivo. However, the 
amount of virus produced by transfection of HEK 293T cells (usually on the order of 106 virions/mL  
of supernatant) is probably much higher than in vivo values, although these await a more detailed 
characterization [66,67].  
The “idealized” FV mutation rate is even higher than that of primate T-cell leukemia viruses 
(PTLVs), which influences infected cells to multiply and, thus, amplify the viral genome by proviral 
expansion, thus avoiding an RNA phase [68,69]. With respect to sequence conservation, it is worth 
mentioning that PTLVs also show weak evidence of human adaptation and human viruses in a given 
area resembling their simian virus counterparts in the same area more than human isolates from a 
different geographic region [70]. It has been suggested that PTLVs are not in need of a genetic 
adaptation to the human host, since they appear to be readily adapted [70]. The multiple trans-species 
transmissions of simian PTLVs to humans represent a comparable situation to FVs [70]. However, 
PTLVs are transmitted among humans, while FVs are apparently not [3,70].  
Compared to the persistent infections observed with HIV, HBV and HCV, FVs give rise to a rather 
low in vivo replication rate in blood and most tissues [48,66,71]. This low in vivo replication might be 
in part responsible for the observed low FV mutation rate; however, it should be noted that the 
mutation rate in cell culture was calculated per replication cycle and the in vivo evolutionary mutation 
rate per year. However, the low FV viremia and the different scales of mutation rate measurements 
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probably do not represent the whole story, because in the SFV system, active viral replication has been 
found in cells of the oral mucosa [66,67], which is consistent with the relative ease of isolating virus 
from NHPs by throat swaps [72]. Thus, the constraints put on the virus in vivo cannot currently be 
reproduced by cell culture experiments, and much more work is needed to understand the FV 
replication in greater detail. In particular, the identification of the exact target cells should be followed 
by a detailed characterization of the process of foamy viral reverse transcription.  
3. FV Recombination 
As noted above, one requisite for virus recombination to occur in the offspring is the infection of 
one host cell by at least two distinct, but genetically-related, viruses; although, a so-called illegitimate 
recombination event between genetically unrelated sequences can occur, but seems to be very  
rare compared to a homologous recombination [10,11]. However, if it takes place, it can have  
really bizarre and unpredictable results. In RV replication, recombination is an obligatory event:  
during reverse transcription, the RT enzyme has to switch RNA templates in order to synthesize the 
double-stranded cDNA genome. From HIV-infection, circulating recombinant forms (CRFs) are 
known that significantly contribute to virus resistance and diversity [23,73]. It has been estimated that 
HIV RT crosses its template at a minimum of 2.8-times per replication cycle [74].  
Given the distinct replication pathways and probably different in vivo target cells between 
orthoretroviruses and spumaretroviruses, a recombination event between these viruses belonging  
to distinct retroviral subfamilies appears very unlikely. Furthermore, such a nota bene illegitimate  
non-homologous recombination event has not been reported from the supposedly thousands of NHPs 
dually-infected with lentiviruses and FVs in NHP centers.  
However, in the unlikely event such a new virus develops, such a new kind of “FV” may acquire 
the pathogenic importance the current FVs lack. A dual infection of FV-HIV in a human case has 
already been reported [75]. In addition, according to Murphy’s Law (“Whatever can go wrong will go 
wrong”), it is advisable to be prepared for a worst-case scenario. Thus, research and surveillance may 
aid in the early detection of recombination leading to novel viruses.  
The first evidence for homologous recombination in FVs in vivo came from the report by Liu et al. 
in which SFVs from chimpanzees were analyzed by single-genome amplification [37]. It was found 
that the original simian FV from chimpanzee (SFVcpz), which apes were infected with, recombined 
with SFVs of lower primates that the chimpanzees hunt for prey [37]. Furthermore, it was shown very 
recently by Galvin et al. [76] that SFVmcy-2 (better known as the laboratory strain Macaca mulatta 
SFV (SFVmac-2)) represents a recombinant form of SFVmcy-1 (SFVmac-1) and an African green 
monkey SFV (SFVagm (SFV-3))-like virus in the receptor-binding domain of env [76]. Furthermore, a 
cell culture model of FV recombination by template switching has been developed that indicated  
an almost 100% probability of the FV RT to switch to a closely-related template, provided both 
templates were expressed in the producer cells at equivalent levels [54]. However, so far, no clear 
picture has emerged from the considerable co-infection by different SFVs among NHPs in the  
wild [37,48] or in captivity [77], because in some monkeys, a recombinant virus appeared, and in 
others, the apparently peaceful coexistence of two strains took place [30,37,78]. In the event of 
persistently infected chimpanzees by lower primate FVs, the situation resembles somehow the reported 
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zoonotic infections of humans by NHP FVs, except that there is no evidence for human-to-human 
transmission of FVs [79]. Given their overall common strategy for genome amplification [2,80], it is 
very unlikely, however, not completely formally excluded yet, that different FVs in vivo make use of 
different target cells (in particular, when heterologous hosts become infected).  
4. Retroviral Genome Diversity 
The overall orthoretroviral genome diversity indicates that env genes are more variable than gag. 
The variability of lentiviral envs is well-known (Figure 3). FVs also appear to be an exception to this 
rule, because they show the opposite feature [81], since their env sequences are much more highly 
conserved than the respective gag genes (Figure 3). One hypothetical argument is that, probably, all 
FVs make use of the same cellular receptor superfamily [82,83] and must conserve recognizing 
epitopes. However, this argument is valid for HIV, as well. Another point concerns the FV replication 
strategy, in particular, the Env topology with leader peptide (LP), surface (SU) and transmembrane 
(TM) proteins that may exert a more rigid Env configuration and, consequently, sequence conservation 
of the FV tripartite than of the normal orthoretroviral bipartite protein [84]. However, this cannot be 
the whole story: e.g., why do we find conserved motifs in all FV LPs that are probably responsible for 
directly contacting cognate FV capsids [85,86], while the latter appear to show such a high variability? 
Figure 3. Overall nucleotide genome conservation of primate lentiviral (A) and primate 
foamy viral (B) genomes. The values are approximate and show a reciprocal feature of 
lentiviral and foamy viral gag and env genes. For clarity, accessory reading frames have 
been omitted (adapted from [81]). 
A different aspect deals with the amino acid distribution in Gag of FVs. More or less all the basic 
residues in foamy viral capsid proteins are represented by arginines [87]. Lysine-poor viral proteins are 
very rare in virology [87]. The FV codon usage indicates that several of the arginine-specifying bases 
in contemporary gag genes were probably lysine-specifying in previous gag genes [87]. The analysis 
of PFV mutants, in which some arginine codons were mutated “back” to lysine codons, excluded a role 
of anti-retroviral restriction factors in lysine exclusion (see below). However, they showed a strong 
interferon (IFN) sensitivity as a possible explanation for lysine-poor Gag in FVs [87]. Thus, host IFN 
selection appears to be a potential long-term driving force shaping current FV Gags (see below).  
Since a functional explanation has not been defined yet, the distribution of variable and conserved 
motifs in FV genomes requires a closer look. Furthermore, it may be that some characteristic features 
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of PFV and other Gags of primate FV origin, such as the nuclear pathway [88,89] or the intra-cellular 
retrotransposition [90,91], may turn out to be particular to PFV and close relatives, uncommon in other 
FVs and not actually representative of the FV-specific replication pathway [80,92]. 
5. Innate Host Defense and Viral Counter-Defense 
Innate host defense and viral counter-defense can determine the outcome of many viral infections, 
resulting in the survival of hosts and viral genomes (positive selection). Central to the innate host 
defense is the interferon (IFN) system. Due to the profound effect of IFN on viral replication, there has 
been mutual evolutionary modulation by viruses on the host’s IFN system and by the host’s IFN system 
on viral genomes [93–95]. Thus, a constant arms race between viruses and hosts emerged [93,94], and 
retroviruses were no exception to the rule [93,94]. 
Early studies have indicated the sensitivity of FV replication to IFNs [96,97]. However, in these 
studies, FVs were regarded as very weak, if at all, inducers of an IFN response [96]. The vulnerability, 
in particular, to type II IFN, was later investigated from a very different angle, when it was shown that 
the addition of γ-antibodies greatly enhanced the chances to isolate FVs in cell culture from peripheral 
blood lymphocytes (PBLs) ex vivo [98] based upon that only 10–20 cells in 106 PBLs appear to contain 
FV DNA on average [48,66,99]. In summary, these studies indicated the extreme vulnerability of FV 
replication to IFN, but left the question of IFN induction by FVs completely open. This was addressed 
in a more recent study by Rua et al. [48], who showed that as with other retroviruses [100,101], the 
toll-like receptor 7 (TLR7) is the main molecule in plasmacytoid dendritic cells (pDCs), the cells in the 
body that preferentially secret type I IFN [93], to sense FVs and to induce a strong IFN response [102]. 
TLR7 recognizes single-stranded RNA. Thus, although reverse transcription has commenced in the 
virus-producing cell far enough to make the virion DNA “infectious” [80,87,103,104], there is 
sufficient virion RNA present to trigger the IFN response. This strong host IFN response might 
indicate that natural infections by FVs were, in ancient times, not as harmless as they are apparently 
now. This scenario can be possibly mimicked by infection of specific IFN knockout mice. On the other 
hand, the vigorous IFN response may be a reason for the inert infection by FVs.  
The induction of IFNs may have resulted in various adaptations that allowed the virus to replicate 
even in their presence. The mode of action of IFNs to establish the antiretroviral state includes  
the hyper-induction of cellular proteins (restriction factors) by which the battle of host vs. virus  
begins. The restriction factors acting on retroviruses have been described in a number of excellent 
reviews [95,105–107]. Therefore, their mechanisms of action against orthoretroviruses will be 
mentioned here only when it is relevant to FV replication. 
However, with FVs, it appears that the host-virus battle is supposedly over and may have occurred 
in evolutionary history. If FV infections were to be completely non-pathogenic, there would be no 
need for the host to adapt to these viruses nor for the virus to counteract the host response. In this 
situation the only “interest” of the virus would be to multiply its genome and propagate without 
affecting the host. This may be an additional reason for the initial difficulty in assigning Bet an 
APOBEC3-counteracting function [61] and for the finding of a bet-minus FV in humans [108]. 
However, we will leave this question open for the time being and will briefly look at the already 
described antiretroviral restriction factors: 
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(A) TRIM5α 
The oligomeric tripartite motif (TRIM) proteins of primates include a large family of antiviral 
effectors that are made of conserved building blocks, namely an N-terminal RING finger domain, one 
or two B-box motifs, a coiled-coil motif (these three are collectively called the RBCC-domain) and the 
C-terminal B30.2/SPRY domain, which confers retrovirus capsid-binding [109,110]. 
TRIM5α proteins inhibit a very early stage of orthoretroviral replication before reverse transcription 
occurs by interfering with capsid breakdown and uncoating of the viral RNA, which is a requisite for 
reverse transcription to take place. To do this, they physically bind to capsids and might induce their 
proteasomal degradation [111–115]. However, the last point is dubious, since inhibition of the 
proteasome does not inhibit the anti-viral activity of TRIM5α [116,117]. Although regions and motifs 
in both proteins have been mapped [116,118], molecular details of how exactly TRIM5α can inhibit 
such diverse retroviruses are largely unknown. Very recently the crystallographic structure of an  
FV N-terminal Gag fragment has been resolved [119]. This analysis revealed not only clues about how 
FV Gag may interact with autologous Env, but also, how TRIM5α might bind to these unique 
retroviral capsids [119]. 
TRIM5α proteins act in a species-specific manner [116]. For instance, the rhesus macaque  
(mac) TRIM5α is active against HIV-1, and vice versa, human TRIM5α prevents an infection by 
SIVmac [116,118]. Since the effect of TRIM5α on viral replication is profound (up to two orders of 
magnitude are regularly observed in experimental settings [116,120]), the presence of TRIM5α has 
been discussed as a strong barrier against viral trans-species transmissions [116,118,121]. However, all 
TRIM5α proteins are inactive against the autologous virus, e.g., HIV-1 will replicate regardless of the 
presence or absence of human TRIM5α, because the retroviral capsid genes evolved to be insensitive 
to “their” TRIM5α proteins, arguing for a very long virus-host adaption. 
FVs are also vulnerable to these proteins [120,122]. As with orthoretroviruses, the restriction is 
dictated by the B30.2 domain and exhibits some species-specificity [120], which suggests a more or 
less development by chance rather than having specific evolutionary implications. Moreover, 
concerning their protein and nucleic acid composition, FVs capsids are very much different from their 
orthoretroviral cousins [2,3]. Thus, the mechanism of TRIM5α action must be very much determined 
from a common structural motif, provided it is similar in both retroviral subfamilies. Since details on 
this mechanism have not been investigated for any of the spumaretroviruses, one cannot tell which 
evolutionary signature in contemporary foamy viral gag genes was imprinted by TRIM5α selection, 
except that such a signature must exist. 
(B) APOBEC3 
If the retroviral genomes were to be reverse transcribed (note that there is a distinctive difference 
between orthoretroviruses and spumaretroviruses with respect to the time-point of reverse transcription 
in the viral replication cycle, which, in the case of the latter, appears to take place to a very large extent 
in virus-producing cells [2,3]), intermediate RNA-DNA hybrids will be generated (Figure 1). The 
single-stranded DNA in these hybrids is the target of apolipoprotein B mRNA-editing enzyme catalytic 
polypeptide-like 3 (APOBEC3) proteins, which deaminate cytosines to uridines [106,123,124]. 
Furthermore, there is a deamination-independent APOBEC3 effect on the reverse transcription of 
lentiviruses [106,125–127]. It is worth mentioning here that there is a marked difference in how 
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lentiviruses and spumaretroviruses react to prevent APOBEC3 packaging. Both virus genera generate  
a viral protein to antagonize APOBEC3. While in most lentiviruses, the Vif protein prevents 
APOBEC3 (mainly APOBEC3G and 3F) protein packaging by delivering them to the cellular 
proteasome for degradation [106,128], the foamy viral accessory Bet protein prevents encapsidation  
by blocking APOBEC3 dimerization and targeting them to form insoluble complexes incapable  
of incorporation into nascent FV capsids [129,130]. FV Bet proteins are not initiating APOBEC3  
protein destruction [57–59]. 
Domains of physical interaction on the side of effector molecules and targets have been  
mapped [57,130]. Recent results from the feline FV system indicate that ORF-2 encodes the 
APOBEC3-interacting sequences [130]. On the other hand, the tas-exon of bet does not contribute 
directly in distracting APOBEC3; however, it may participate in the high bet expression level.  
The ORF-2 sequences evolutionarily shaped the genomic APOBEC3 locus and vice versa [57]. 
ORF-2/bet sequences belong to the more variable genomic regions of FVs and impose a high value  
of non-synonymous vs. synonymous mutations. This implies that, similar to the situation in the 
lentivirus genus [123,131], there is some species specificity in ORF-2/Bet to antagonize APOBEC3 
proteins [57,129,130]. 
For lentiviruses, it has been proposed that the virus (HIV-1) benefits from a partially active 
APOBEC3 by exploiting this particular cellular mechanism of innate immunity to enhance viral 
diversity [132–134]. The strict conservation of their genomes illustrates that this is not an option for 
FVs. Moreover, the development of a viral protein to counteract APOBEC instead of evolving the gag 
genes, as a way not to package APOBECs, shows that either the latter is not so easily possible or that 
homologous-insensitive TRIM5α (see above) constitutes the older antiviral host activity. However, 
sequence evidence argues against the latter possibility [135]. Clearly, the clarification of this response 
needs further experimental approaches, in particular, the species specificity of FVs to antagonize 
APOBEC3 proteins requires further analysis.  
(C) Tetherin 
From the viewpoint of virus replication, tetherin (CD317) is the last of the IFN-inducible factors 
that restrict FV replication, because it acts on the cell-free virion [136,137]. Tetherin is a type II  
trans-membrane protein with an N-terminal trans-membrane domain, followed by an extra-cellular 
domain that adopts a coiled-coil structure and a C-terminal glycosyl-phosphatidylinositol (GPI)  
anchor [107,138]. Due to its membrane-sticking features, tetherin inhibits the generation of free 
enveloped virions (not only form orthoretroviruses) [139,140].  
Tetherin forms homodimers [107,138,141,142]. Dimerization is a requisite to act on lentiviruses; 
thereby, the Vpu or the Nef proteins have evolved to counteract and degrade tetherin [107,138,141,142]. 
In HIV-2, where a vpu ORF does not exist, the Env protein fulfils this function [107,138,141,142]. 
However, dimerization appears to be not essential for FV restriction, whereas the membrane insertion 
on both sides is [143]. FVs have no particular ORF to counteract tetherin. This feature might result in 
the low viremia and cell-associated nature of FV infections. Similar to FIV, which also does not 
contain a tetherin-antagonizing protein [144], this obviously does not prevent infections by FVs.  
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(D) SamHD1 
Weather the Sterile motif domain- and HD domain-containing protein 1 (SamHD1), which restricts 
HIV replication in myeloid cells by alteration of the nucleotide pool required for reverse transcription 
and which is counteracted by HIV-2 (and related viruses), Vpx protein [145] is also able to restrict FV 
replication and was investigated with a negative result recently [146]. Since SanHD1 acts on the 
nucleotide pool required for reverse transcription, it appeared a priori unlikely that it is able to restrict 
FVs, if added to target cells. Due to the feature of late reverse transcription, the FV genome already 
consists of DNA (Figure 1).  
6. On the Origin of PFV and Further Human FV Infections 
Early reports presented serological evidence of a human FV [147,148]. However, these studies 
could not be confirmed upon further investigations [149,150]. Furthermore, when an FV from 
chimpanzees was molecularly cloned and sequenced, it was suggested that the PFV isolate, which was 
obtained in 1970 from a Kenyan patient [151], might actually represent an ape virus [152] (Figure 4).  
However, a more detailed evaluation, including DNA sequences, which became only available 
recently [48,50], reveals that the SFVs from chimpanzees present a wider sequence spectrum than  
the SFVs from gorillas (Figure 5). This finding represents only a very indirect support for the 
phylogeographic origin of FV sequences, because the actual geographic origin of the gorilla whose 
SFV sequence was reported first [48,50] is dubious. All other SFVgor sequences [48] were derived 
from animals stemming from a more limited area compared to the FVs derived from chimpanzees. 
These data are best compatible with the assumption of a strain-specific transmission pattern according 
to mother-to-child transmission and social groups [30]. In addition, they reflect behavioral differences 
between chimpanzees and gorillas, e.g., a more aggressive behavior of the former. Surely, more 
sequencing data from great ape FVs should reveal a better evolutionary relationship of FVs. However, 
PFV to SFV being almost identical in P.t. schweinfurthii points to these chimpanzee subspecies as a 
potential transmitter of this virus.  
Aside from PFV, there are many examples of human infections by NHP FVs among personnel in 
primate centers, zoos or other facilities housing NHPs or due to NHP biological materials [79]. 
Furthermore, African bushmeat hunters appear to be at high risk of SFV infections [48]. Another  
risk to acquire an FV infection exists for humans living close to Asian temple sites or other places, 
where humans often encounter free roaming monkeys [153]. In most cases, when humans  
acquired an FV infection, it was due to wounds in recipients and mostly from donor bites or deep 
scratches [48,79]. The infected humans remained unaware of their infection until—sometimes after 
decades [48,79]—researchers investigated their blood and were able to isolate virus in addition to 
finding serologic and nucleic acid evidence of infection [3,48]. However, retroviral infections 
sometimes go for long periods of time unnoticed and, in addition, pathological consequences may be 
rather subtle [154]; therefore, a careful follow up of the human cases is advisable. However, up to now, 
not a single case of human-to-human transmission has been reported. It appears as if mainly social 
behavior changes associated with human evolution were linked to a loss in FV susceptibility. 
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Figure 4. Phylogeny of current endogenous and exogenous FV pol amino acid sequences 
(from the active center-specifying integrase sequences and comprising 142 codons). A 
neighbor-joining tree was calculated by using the Maximum Composite Likelihood method 
with a bootstrap test of 10,000 replicates. BFV, bovine FV (NP_044929.1); EFV equine 
FV (NP_054716.1); PFV, prototypic FV (in red) (Y07725.1); SFVcpz, SFV from 
chimpanzee (CCP47057); SFVgor, SFV from gorilla (AY195688.1); SFVora, SFV from 
orangutan (CAD67562); SFVagm, African green monkey (Cercopithecus aethiops) FV 
(YP_001956722.2); SFVcha, SFV from Chlorocebus aethiops (CAM34599); SFVcep, 
SFV from Cercopithecus pygerythrus (AAV92627); SFVman, SFV from mandrill 
(ADO65890.1); SFVpap, SFV from Papio (CAM34655); SFVmcy (previously SFVmac) 
from Macaca mulatta, SFV from Macaca cyclopis (CAA41394.1); SFVtup, SFV from 
Tupaia [155] (AGN49359); SFVspm, SFV from spider monkey (ABV59399.1); SFVmar, 
SFV from marmosets (ADE06000.1); SFVsqu, SFV from squirrel monkeys (ADE05995.1); 
FFV, feline FV (NP_056914); Puma, FV from Puma concolor (AGC11913); RaFV-1, FV 
from the bat Rhinolophus affinis (AFK85015); SloEFV, endogenous FV from sloths 
(Katzourakis et al., 2009); CoeEFV, endogenous FV in the coelacanth (Latimeria) genome 
(JX006241.1); platyfish EFV, endogenous FV from platyfish (M. Schartl, personal 
communication); zebrafish EFV, zebrafish (M. Schartl, personal communication); and Cod 
EFV, codfish (M. Schartl, personal communication) genomes; integrase encoding sequences 
of the macaque simian immunodeficiency virus (SIVmac in magenta) (AAC57420.1) 
served as the outlier; the endogenous FV sequence from aye-aye (PSFVaye) [156] was not 
incorporated, because integrase sequences are not available. 
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Figure 5. A 425-nucleotide fragment from the conserved region of the integrase domain  
of pol was used to establish the phylogenetic tree demonstrating the phylogenetic relations 
of SFVcpz, PFV and SFVgor. The position of the proviral PFV (red) sequence and  
other proviral plasmids (blue) are indicated. SIVmac (magenta) served as an outlier.  
Pan paniscus is Bonobo. 
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One point deserving further discussion is that FV transmitted from an NHP to a human did not yet 
evolve into a human FV, in sharp contrast to the development of HIV from simian immunodeficiency 
virus (SIV) transmitted to humans [175]. Even after decades of infection, the FV remained stable and 
maintained the genetic signature of the original infectious agent, i.e., the viral mutation rate in the new 
human host was not different from that in the natural ape or monkey host [48,79]. This is one of the 
clearest arguments for the non-pathogenic nature of FV infections. On the other hand, lessons from 
PTLV teach that the lack of human adaptation does not automatically preclude viral pathogenesis [70]. 
7. Exogenous FVs in the Animal Kingdom 
The overall distribution of FV sequences indicates that these viruses are extremely widespread  
in the animal kingdom (Figure 4). FVs have not only been frequently found in NHPs of Old and  
New World origins, with a prevalence depending on the individual age and mounting up to 100% in 
grown up animals in the wild [30,37,77]. FVs are also present in prosimians, felines, bovines and 
equines [3,155,157,158]. Isolated reports on FVs from sheep [159], bison [160] and sea lions [161] 
suggest their presence in Bovidae and sea mammals. A notable exception is rodents, for which a 
specific FV has not been reported yet. Recently, Blasse et al. reported even the age-dependent 
infection of chimpanzees by more than one FV [30]. However, as to the extent of cross-neutralization 
of the superinfecting virus by immune response against the originally infecting FV, this has not been 
analyzed yet. 
The various bat species are a major reservoir of viral infections, which may be eventually 
transmitted to humans as zoonoses; rhabdo-, corona-, filo-, orthomyxo-, paramyxo- and herpes-viruses 
are only some examples [162–165]. It came, therefore, as no major surprise that the detection of 
exogenous FV sequences upon screening of fecal samples from Asian bat species was reported 
recently by Wu et al. [166]. The finding of FVs in a such a diverse and old order illustrates the very 
old age of these viruses and asks for a more systematic screening and molecular characterization of 
FVs isolated from animals (not necessarily only mammals; see below) close to evolutionary branch 
points or otherwise interesting to science. 
8. Endogenous FVs 
If retroviruses get access to gametocytes, the result can be an endogenous form of the virus, which 
than mutates “neutrally” and is passaged in the germline along with the host cell genome and no longer 
transmitted as an exogenous virus [167,168]. In the vast majority of cases, “lethal” mutations 
accumulate over time in replication-required viral reading frames [167]. Approximately 8% of the 
human genome is made up by endogenous retroviruses, and a further 30%–40% of sequences are the 
result of reverse transcription [167].  
Based on some sequence homology, the endogenous retrovirus-like (ERV) family L has been 
proposed to represent distantly related human and animal endogenous FVs [169]. However, the stretch 
of homology is rather short and does not hold up for the rest of the viral genome [170]. Thus, it was 
almost two decades before researchers again looked for endogenous FVs. They came up with some 
interesting findings from several pretty much different species. In any case, they demonstrated the very 
old age of FVs. 
Viruses 2013, 5 2363 
 
Firstly, Katzourakis et al. [171] reported their presence in the two- and three-toed sloths from South 
America (SloEFV) (Figure 4). Both species were separated approximately 21 million years ago 
(MYA). Since these endogenous elements were absent in other Xenarthrans species (e.g., ant bears 
and armadillos), which separated from the sloths 55 MYA, the authors conclude the establishment of 
SloEFV during this period (55 MYA–21 MYA) and the previous presence of exogenous FVs [171]. 
Secondly, Han and Worobey published [156] an endogenous FV sequence (PSFVaye), which was 
derived from the Madagascar aye-aye lemur (Daubentonia madagascarensis), a primitive prosimian. 
This suggests that exogenous FVs were present before the split of Strepsirrhini (mainly galagos, loris 
and lemurs) and Haplorhini (mainly the simians of the Old and New World) around 85 MYA, because 
the aye-aye is phylogenetically basal to the current lemurs [156].  
Thirdly, it was reported again by Han and Worobey [172] that, surprisingly, the Coelacanth 
(Latimeria) genome harbors endogenous FV-like elements (CoeEFV) (Figure 4). Latimeria is a “living 
fossil”, believed to be a side branch of those now extinct lobe-finned fish, from which all current land 
vertebrates developed. If FVs were indeed to be present in these species, the FV-host coevolution 
represents an age of over 400 MYA, by far oldest known virus-host relationship. For instance, they 
would be approximately 30-times older than the oldest endogenous lentivirus we know [173].  
Fourthly, Schartl et al. recently reported the discovery of fish endogenous FVs from the platyfish 
(Xiphophorus) and the cod species [174]. Furthermore, FV-like sequences were previously described 
in the zebra fish genome [175]. These discoveries do not necessarily extend the age of FVs; rather, the 
finding in another vertebrate order, in addition to mammals, supports the notion of the remarkable 
evolutionary success of this retroviral subfamily. Not all fish species harbor endogenous FVs [174], 
and the finding of almost intact copies of some FV genes [174], that is, without the accumulation of 
“lethal” mutations, might indicate the recent evolutionary invasion from exogenous FV. 
9. Conclusions 
1. Exogenous FVs might be present in species outside the class of placental Mammalia.  
Therefore, it will be scientifically extremely interesting to see FV isolates/sequences from Marsupialia, 
monotremes, birds, reptiles and amphibians. Even their presence as exogenous viruses in some fish 
species is not excluded, and the very much cell-associated nature of the agents might have yet 
prevented their detection. 
2. The very long coevolution with animals may be the real reason for the benign nature of FV 
infections. For reasons of scientific consistency, it might be theoretically distracting and, for reasons of 
vector application, probably, medically beneficial that a genuine human FV does apparently not exist. 
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